Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference





Live video webcast presentation on Wednesday, January 26


th


at 9:00 AM ET


CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) —

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that

Dr. Klaus Paulini, Chief Executive Officer

of Aeterna Zentaris, will present at the

Virtual Investor 2022 Top Picks Conference

on Wednesday, January 26, 2022 at 9:00 AM ET.

As part of the virtual event, the Company will provide a brief presentation, followed by a moderated discussion and an interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at

virtualinvestorco.com

. The Company will answer as many questions as possible during the event.

A

live video webcast

of the presentation will be available on the

Events

page in the

Investors

section of the Company’s website (

www.zentaris.com

). A webcast replay will be available two hours following the live presentation and will be accessible for one year.


About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company’s lead product, macimorelin (Macrilen



), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson’s disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and chlamydia.

For more information, please visit

www.zentaris.com

and connect with the Company on

Twitter

,

LinkedIn

and

Facebook

.


Investor Contact:

Jenene Thomas

JTC Team

T (US): +1 (833) 475-8247

E:

[email protected]


Primary Logo